JP2019531755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531755A5 JP2019531755A5 JP2019522945A JP2019522945A JP2019531755A5 JP 2019531755 A5 JP2019531755 A5 JP 2019531755A5 JP 2019522945 A JP2019522945 A JP 2019522945A JP 2019522945 A JP2019522945 A JP 2019522945A JP 2019531755 A5 JP2019531755 A5 JP 2019531755A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- receptor
- gene
- population
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 82
- 210000004027 cell Anatomy 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 101710163270 Nuclease Proteins 0.000 claims description 36
- 239000013607 AAV vector Substances 0.000 claims description 33
- 108700019146 Transgenes Proteins 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 18
- 210000004698 lymphocyte Anatomy 0.000 claims description 15
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims description 8
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 7
- 210000000234 capsid Anatomy 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 230000007954 hypoxia Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 108010067390 Viral Proteins Proteins 0.000 claims description 5
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims description 4
- 102100024263 CD160 antigen Human genes 0.000 claims description 4
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 claims description 4
- 108090000397 Caspase 3 Proteins 0.000 claims description 4
- 102000004018 Caspase 6 Human genes 0.000 claims description 4
- 108090000425 Caspase 6 Proteins 0.000 claims description 4
- 108090000567 Caspase 7 Proteins 0.000 claims description 4
- 102000004068 Caspase-10 Human genes 0.000 claims description 4
- 108090000572 Caspase-10 Proteins 0.000 claims description 4
- 102100029855 Caspase-3 Human genes 0.000 claims description 4
- 102100038902 Caspase-7 Human genes 0.000 claims description 4
- 102100026548 Caspase-8 Human genes 0.000 claims description 4
- 108090000538 Caspase-8 Proteins 0.000 claims description 4
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 4
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 4
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 4
- 101000687344 Homo sapiens PR domain zinc finger protein 1 Proteins 0.000 claims description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 4
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims description 4
- 101710146672 Interleukin-10 receptor subunit alpha Proteins 0.000 claims description 4
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims description 4
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 claims description 4
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 4
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 4
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 4
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 4
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 4
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 4
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims description 4
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 4
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 4
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 4
- 101710110531 Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 4
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 4
- 101710110541 Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 108091007178 TNFRSF10A Proteins 0.000 claims description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 4
- 101710178278 Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 4
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 4
- 230000030833 cell death Effects 0.000 claims description 4
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 101100011377 Caenorhabditis elegans egl-9 gene Proteins 0.000 claims description 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims description 3
- 108700001531 Protozoan Genes Proteins 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 108010049207 Death Domain Receptors Proteins 0.000 claims description 2
- 102000009058 Death Domain Receptors Human genes 0.000 claims description 2
- 102000010170 Death domains Human genes 0.000 claims description 2
- 108050001718 Death domains Proteins 0.000 claims description 2
- 102100037249 Egl nine homolog 1 Human genes 0.000 claims description 2
- 101710111663 Egl nine homolog 1 Proteins 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 229940125581 ImmunityBio COVID-19 vaccine Drugs 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 108010089430 Phosphoproteins Proteins 0.000 claims description 2
- 102000007982 Phosphoproteins Human genes 0.000 claims description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 2
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 2
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 2
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 claims description 2
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 claims description 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- FUHMZYWBSHTEDZ-UHFFFAOYSA-M bispyribac-sodium Chemical compound [Na+].COC1=CC(OC)=NC(OC=2C(=C(OC=3N=C(OC)C=C(OC)N=3)C=CC=2)C([O-])=O)=N1 FUHMZYWBSHTEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 claims description 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000005782 double-strand break Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims 2
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101710167716 Cytotoxic and regulatory T-cell molecule Proteins 0.000 claims 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 claims 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 claims 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims 1
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 claims 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 claims 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims 1
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 claims 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 claims 1
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 claims 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims 1
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 claims 1
- 102100029454 T cell receptor alpha chain MC.7.G5 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 201000009613 breast lymphoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102000000279 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 2
- 108050008721 Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- -1 Csm2 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065676A JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413814P | 2016-10-27 | 2016-10-27 | |
| US62/413,814 | 2016-10-27 | ||
| US201762452081P | 2017-01-30 | 2017-01-30 | |
| US62/452,081 | 2017-01-30 | ||
| PCT/US2017/058605 WO2018081470A1 (en) | 2016-10-27 | 2017-10-26 | Viral methods of making genetically modified cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065676A Division JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531755A JP2019531755A (ja) | 2019-11-07 |
| JP2019531755A5 true JP2019531755A5 (enExample) | 2020-12-17 |
Family
ID=62024054
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522945A Pending JP2019531755A (ja) | 2016-10-27 | 2017-10-26 | 遺伝子改変細胞を作製するウイルス法 |
| JP2019522944A Pending JP2019536447A (ja) | 2016-10-27 | 2017-10-26 | Ｔ細胞療法のウイルス法 |
| JP2022065676A Pending JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
| JP2022185536A Pending JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522944A Pending JP2019536447A (ja) | 2016-10-27 | 2017-10-26 | Ｔ細胞療法のウイルス法 |
| JP2022065676A Pending JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
| JP2022185536A Pending JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190374576A1 (enExample) |
| EP (2) | EP3532079A4 (enExample) |
| JP (4) | JP2019531755A (enExample) |
| CN (2) | CN111344396A (enExample) |
| AU (3) | AU2017347848A1 (enExample) |
| CA (2) | CA3041831A1 (enExample) |
| GB (3) | GB2573664B (enExample) |
| WO (2) | WO2018081476A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| EP3262173A2 (en) | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| AU2016225179C1 (en) | 2015-02-23 | 2022-11-03 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
| WO2017077394A2 (en) | 2015-11-04 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| EP4047092B1 (en) | 2016-04-13 | 2025-07-30 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| WO2018081476A2 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| EP4644554A2 (en) | 2016-10-31 | 2025-11-05 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| JP2020530307A (ja) * | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| CN111565730B (zh) * | 2017-11-09 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰 |
| MA51107A (fr) | 2017-12-05 | 2020-10-14 | Vertex Pharma | Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| US11713446B2 (en) * | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| EP3749767A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| WO2019150203A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112368003A (zh) | 2018-04-27 | 2021-02-12 | 艾欧凡斯生物治疗公司 | 肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途 |
| JP7575949B2 (ja) * | 2018-04-27 | 2024-10-31 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現 |
| CN112218882A (zh) * | 2018-04-27 | 2021-01-12 | 西雅图儿童医院（Dba西雅图儿童研究所） | Foxp3在经编辑的cd34+细胞中的表达 |
| SG11202010763VA (en) * | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| US20210277120A1 (en) * | 2018-07-18 | 2021-09-09 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| CN110818802B (zh) * | 2018-08-08 | 2022-02-08 | 华夏英泰（北京）生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
| CN113226336B (zh) * | 2018-12-17 | 2024-03-15 | 苏州克睿基因生物科技有限公司 | 一种在细胞中递送基因的方法 |
| US20220017863A1 (en) * | 2019-02-08 | 2022-01-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sirt2-ablated chimeric t cells |
| WO2020172328A1 (en) * | 2019-02-20 | 2020-08-27 | Rutgers, The State University Of New Jersey | Expansion of natural killer and chimeric antigen receptor-modified cells |
| EP3931375A4 (en) * | 2019-03-01 | 2022-12-07 | Fred Hutchinson Cancer Center | Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| PH12021552383A1 (en) * | 2019-03-27 | 2022-06-13 | Res Inst Nationwide Childrens Hospital | Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses |
| US20220213469A1 (en) * | 2019-04-30 | 2022-07-07 | The Broad Institute, Inc. | Methods and compositions for barcoding nucleic acid libraries and cell populations |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| EP4017988A4 (en) * | 2019-08-19 | 2023-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | METHODS AND COMPOSITIONS FOR ENHANCEMENT AAV-MEDIATED HOMOLOGUE RECOMBINATION USING RIBONUCLEOTIDE REDUCTASE INHIBITORS |
| GB201913898D0 (en) * | 2019-09-26 | 2019-11-13 | Lightbio Ltd | Nucleic acid construct |
| JP2022552819A (ja) * | 2019-10-08 | 2022-12-20 | パクト ファーマ インコーポレイテッド | 遺伝子改変自己ｔ細胞免疫療法を使用する治療方法 |
| US20230053028A1 (en) * | 2019-12-18 | 2023-02-16 | Editas Medicine, Inc. | Engineered cells for therapy |
| IL295871A (en) * | 2020-02-28 | 2022-10-01 | Genentech Inc | Efficient genome editing in primary myeloid cells |
| CN111420025B (zh) * | 2020-04-28 | 2021-06-11 | 中国药科大学 | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 |
| AU2021265797A1 (en) | 2020-04-28 | 2022-12-08 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| IL298510A (en) | 2020-06-12 | 2023-01-01 | Nkarta Inc | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| AU2021392094A1 (en) * | 2020-12-01 | 2023-07-06 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| EP4259805A4 (en) * | 2020-12-08 | 2025-07-23 | The Regents Of Univ Of California | CRISPR RIBONUCLEOPROTEIN COMPLEX GENOME EDITING OF HUMAN INNATE IMMUNE CELLS |
| CN113046357B (zh) * | 2021-01-25 | 2023-05-16 | 柳州市柳铁中心医院 | 一种乐伐替尼耐药基因dusp9、其筛选方法及应用 |
| CN112941105A (zh) * | 2021-02-08 | 2021-06-11 | 江西农业大学 | 一种m6A“阅读器”YTHDF2基因改造方法及其应用 |
| CN114058619B (zh) * | 2021-11-19 | 2023-11-14 | 中国农业科学院兰州兽医研究所 | Riplet敲除细胞系的构建及作为小核糖核酸病毒科病毒疫苗生产细胞系的应用 |
| CN114621929B (zh) * | 2021-12-21 | 2023-05-30 | 河南省肿瘤医院 | 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用 |
| JP2025509760A (ja) * | 2022-03-16 | 2025-04-11 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 細胞療法のための遺伝子操作されたｔ細胞 |
| CN119923264A (zh) * | 2022-09-27 | 2025-05-02 | 基因泰克公司 | 抑制基因毒性应激以改善t细胞工程化 |
| EP4661970A1 (en) * | 2023-02-07 | 2025-12-17 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Therapeutic base editing |
| WO2024220789A1 (en) * | 2023-04-21 | 2024-10-24 | Regents Of The University Of Minnesota | Cell lines and methods for producing recombinant adeno-associated virus |
| WO2025179160A1 (en) * | 2024-02-21 | 2025-08-28 | Research Institute At Nationwide Children's Hospital | Methods of increasing nk cell efficacy through inhibition of v-domain ig suppressor of t cell activation (vista) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012078540A1 (en) * | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| AU2014235968B2 (en) * | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| WO2014184744A1 (en) * | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| CN110713995B (zh) * | 2013-10-17 | 2023-08-01 | 桑格摩生物科学股份有限公司 | 用于核酸酶介导的基因组工程改造的递送方法和组合物 |
| EP3800248A3 (en) * | 2014-04-18 | 2021-08-04 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| AU2015339743C1 (en) * | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| US20180119174A1 (en) * | 2015-05-13 | 2018-05-03 | Seattle Children's Hospita (dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
| WO2017023803A1 (en) * | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| CN109311984A (zh) * | 2016-03-11 | 2019-02-05 | 蓝鸟生物公司 | 基因组编辑的免疫效应细胞 |
| SG11201808831TA (en) * | 2016-04-15 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018081476A2 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| JP2020530307A (ja) * | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| CN111565730B (zh) * | 2017-11-09 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰 |
-
2017
- 2017-10-26 WO PCT/US2017/058615 patent/WO2018081476A2/en not_active Ceased
- 2017-10-26 GB GB1906850.1A patent/GB2573664B/en active Active
- 2017-10-26 GB GB1906849.3A patent/GB2573663B/en active Active
- 2017-10-26 GB GB2210377.4A patent/GB2607227B/en active Active
- 2017-10-26 CN CN201780082010.6A patent/CN111344396A/zh active Pending
- 2017-10-26 JP JP2019522945A patent/JP2019531755A/ja active Pending
- 2017-10-26 WO PCT/US2017/058605 patent/WO2018081470A1/en not_active Ceased
- 2017-10-26 EP EP17865054.5A patent/EP3532079A4/en not_active Withdrawn
- 2017-10-26 JP JP2019522944A patent/JP2019536447A/ja active Pending
- 2017-10-26 CN CN201780082012.5A patent/CN110545827A/zh active Pending
- 2017-10-26 AU AU2017347848A patent/AU2017347848A1/en not_active Abandoned
- 2017-10-26 CA CA3041831A patent/CA3041831A1/en active Pending
- 2017-10-26 EP EP17865925.6A patent/EP3532075A4/en not_active Withdrawn
- 2017-10-26 AU AU2017347854A patent/AU2017347854B2/en active Active
- 2017-10-26 CA CA3041835A patent/CA3041835A1/en active Pending
-
2019
- 2019-04-19 US US16/389,586 patent/US20190374576A1/en not_active Abandoned
- 2019-04-19 US US16/389,612 patent/US20190382799A1/en not_active Abandoned
-
2022
- 2022-04-12 JP JP2022065676A patent/JP2022087214A/ja active Pending
- 2022-11-21 JP JP2022185536A patent/JP2023010842A/ja active Pending
-
2023
- 2023-02-28 AU AU2023201224A patent/AU2023201224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531755A5 (enExample) | ||
| JP2023010842A (ja) | Ｔ細胞療法のウイルス法 | |
| US11098325B2 (en) | Adeno-associated viral vectors for gene therapy | |
| JP2019536447A5 (enExample) | ||
| US20210388389A1 (en) | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells | |
| CA3182286A1 (en) | Selection by essential-gene knock-in | |
| CN113508178A (zh) | 用于调节经工程化的基因的表达的微环境传感器 | |
| Hargrove et al. | High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′ γ globin gene regulatory element and integrates as tandem copies in erythroid cells | |
| EP3619313B9 (en) | Tumor environment-specific expression of chimeric antigen receptors | |
| WO2017087961A1 (en) | Hematopoietic cell gene editing | |
| CN114364799A (zh) | 编辑造血干/祖细胞中bcl11a基因的方法 | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| Kararoudi et al. | Highly efficient site-directed gene insertion in primary human natural killer cells using homologous recombination and CRISPaint delivered by AAV | |
| Skeate et al. | A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells | |
| HK40063018A (en) | Microenvironment sensors to regulate engineered gene expression | |
| US20220064668A1 (en) | Modified adeno-associated viral vectors for use in genetic engineering | |
| Rajalingam | Killer Cell Immunoglobulin‐Like Receptors (KIR) in Clinical Transplantation | |
| HK40018037A (en) | Viral methods of t cell therapy | |
| HK40032623A (en) | Viral methods of making genetically modified cells |